Is Transgene SA halal to invest in?

According to Musaffa's Shariah screening methodology, Transgene SA (TNG.PA) is currently classified as NOT HALAL as of July 2025. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Transgene SA a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Transgene SA using these criteria to determine its compliance status.

Can Muslims buy shares of Transgene SA?

Muslim investors may consider investing in Transgene SA if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Transgene SA classified as NOT HALAL?

Musaffa determines the Shariah status of Transgene SA by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Transgene SA updated?

The Shariah compliance status of Transgene SA may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Transgene SA become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Transgene SA?

You can check the latest Shariah compliance status of Transgene SA on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Transgene SA TNG.PA

€0.83 €0.01 (1.60%) 1D

Last Updated: May 15, 12:00 AM·XPAR

TNG.PA Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: July 19, 2025

Report Source: 2024 Annual Report

Analyst's Ratings for Transgene SA (TNG.PA)

Based on 7 analysts giving stock ratings to Transgene SA in the past 3 months

Strong
SellSellHoldBuyStrong
Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Transgene SA. Stock Analysis TNG.PA

France Health Care Micro Cap Report: 2024 Annual

Transgene SA is a biotechnology company that focuses on designing and developing targeted immunotherapies for the treatment of cancer. The company is headquartered in Illkirch-Graffenstaden, Grand Est and currently employs 156 full-time employees. The firm designs and develops immunotherapy products to treat cancer and infectious diseases. These products use viral vectors to directly or indirectly destroy diseased cells. The firm has approximately three products in clinical development: two immunotherapy products for cancer treatment and an anti-infective immunotherapy product for chronic hepatitis B. The firm also has various other programs based on its viral vector technology in research or in pre-clinical or clinical development. The firm's activities are focused on human health and, in particular, the research and development of immunotherapy products, including therapeutic vaccines and oncolytic viruses in the field of cancer and infectious diseases. The firm's principal products include TG4010 (MVA-MUC1-IL2), Pexa-Vec (VV-TK-GM-CSF), TG6002 (VV-TK-RR-FCU1), TG1050 (Ad5-HBV) and TG4001 (MVA-HPV-IL2).

Key Statistics of Transgene SA (TNG.PA)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

€0.83€0.85

Today's Open

€0.85

Volume

48.72K

P/E Ratio (TTM)

52 Week Range

€0.53€1.50

Market Cap

208.49M

Avg. Volume

11.45K

Dividend Yield

Financial Metrics & Statements of Transgene SA (TNG.PA)

FAQ's for Transgene SA (TNG.PA)

According to Musaffa’s Shariah screening methodology, Transgene SA (TNG.PA) is currently classified as NOT HALAL as of July 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.